Stock Price Quote

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE1090.050.95 (+0.09 %)
PREV CLOSE ( ) 1089.10
OPEN PRICE ( ) 1095.00
BID PRICE (QTY) 1090.00 (5)
OFFER PRICE (QTY) 1090.55 (32)
VOLUME 24720
TODAY'S LOW / HIGH ( )1087.20 1103.00
52 WK LOW / HIGH ( )547.75 1171.95
NSE1092.003.35 (+0.31 %)
PREV CLOSE( ) 1088.65
OPEN PRICE ( ) 1095.00
BID PRICE (QTY) 1092.00 (26)
OFFER PRICE (QTY) 1092.05 (1)
VOLUME 324134
TODAY'S LOW / HIGH( ) 1087.70 1102.90
52 WK LOW / HIGH ( )547.9 1172.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-05 1995
Management Info
Pankaj R Patel - Chairman Sharvil P Patel - Managing Director
Registered Office

Address Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway,
Ahmedabad,
Gujarat-382481

Phone 079-71800000 / 48040000

Email dhavalsoni@zyduscadila.com

Website www.zyduscadila.com

Registrars Details
Link Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE, MCX

NEWS

20Jun Zydus Lifesciences informs about detai
Pursuant to regulation 39(3) of the Listing Regulations, Zydus Lifescien..
17Jun Zydus Lifesciences informs about analy
Zydus Lifesciences has informed that the management of the Company will..
14Jun Zydus Lifesciences gets USFDA’s tentat
Zydus Lifesciences has received tentative approval from the United State..
14Jun Zydus Lifesciences jumps on getting US
Zydus Lifesciences is currently trading at Rs. 1103.45, up by 13.15 poin..
04Jun Zydus Lifesciences informs about loss
Pursuant to regulation 39(3) of the Listing Regulations, Zydus Lifescien..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit1405234415
Gross Profit 16849 42398
Operating Profit 1930351435
Net Sales 33324108187

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  7000.00 (0.98%)
M.Cap ( in Cr)16121.44
Glaxosmithkline Phar (BSE)
peergroup  2569.30 (1.75%)
M.Cap ( in Cr)43667.79
Bharat Parenterals (BSE)
peergroup  1396.00 (1.95%)
M.Cap ( in Cr)911.43
Procter&Gamble Healt (BSE)
peergroup  5016.15 (0.42%)
M.Cap ( in Cr)8356.13
Trident Lifeline (BSE)
peergroup  194.00 (7.18%)
M.Cap ( in Cr)223.08

Shareholding Pattern

PROMOTERS 74.98%
MUTUAL FUNDS/UTI 6.71%
NON-INSTITUTION 6.66%
FI/BANKS/INSURANCE 5.74%
GOVERNMENT 0%
FII 0%

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.